2025 nr 565 midterm 2025) comprehensive questions and verified answers (detailed & elaborated)
actual exam 2025 test 100% solved 2025!!
APRN prescribing role - -Prescriptive authority for nurse practitioners also regulates prescribing
rights beyond medications and controlled substances. These rights include therapeutic devices and
services and are outlined in state practice laws and regulations and include Durable Medical
Equipment (DME) such as wheelchairs, power scooters, hospital beds, portable oxygen equipment,
handicap placards, etc. and medical services such as Physical Therapy (PT), Occupational Therapy
(OT), home health services, etc. Prescriptive authority encompasses more than writing a prescription
correctly. It requires adherence to ethical guidelines to ensure that patients are safeguarded from
harm. Ethical prescribing starts with being well-informed about medications. Mechanism of action,
efficacy, and safety are important considerations, as are a patient's distinct needs and
circumstances, including the number of medications prescribed (Mitchell & Oliphant, 2016). Most
patients receiving a prescription are taking other medications, whether prescription or over-the-
counter. Appropriate selection, dosing, and duration of pharmaceutical agents are key to maximizing
outcomes and minimizing adverse effects
--benefits of full practice authority - -Nurse practitioners have the autonomy to evaluate patients,
diagnose, order and interpret tests, initiate and manage treatments and prescribe medications,
including controlled substances without physician oversight
--promoting positive outcomes through prudent prescribing practices - -Administering medications
and prescribing medications are two distinct processes. Prescription writing requires prudent and
deliberate decision-making processes to maintain patient safety and reduce liability, including:
*documentation of a provider-patient relationship for the recipient of the prescribed medications
*documentation of a thorough history and physical examination for the recipient
*documentation of discussions regarding risk factors, side effects, or therapy options
*documentation of drug monitoring or titration plan, if applicable
*documentation of consultations, if any
avoidance of prescribing medications for self, family, or friends
Rational drug selection requires a logical approach that includes the formulation of a diagnosis based
on clinical reasoning and the selection and monitoring of the most appropriate pharmacological
treatment
Considerations include: Cost, guidelines, availability, interactions, side effects, allergies,
hepatic/renal functions, need for monitoring, & special populations
--Beer's Criteria - -identifies drugs with a high likelihood of causing adverse effects in older adults.
Accordingly, drugs on this list should generally be avoided in adults older than 65 years except when
the benefits are significantly greater than the risks.
--Pharmacodynamics - -the study of the biochemical and physiologic effects of drugs on the body
and the molecular mechanisms by which those effects are produced
--Pharmacokinetics - -the study of drug movement throughout the body
,--Pharmacogenomics - -the study of how genes affect a person's response to drugs. The purpose of
this is to combine the sciences of genomics and pharmacology to provide individualized, targeted,
safe drug therapies to patients
--CYP450 inducers - -Inducers are xenobiotics (medications and environmental agents) that elevate
CYP450 enzyme activity by increasing enzyme synthesis. This action leads to additional sites available
for biotransformation. The increased number of sites enhances medication metabolism, decreasing
the concentration of the "parent drug" while increasing metabolite production.
Inducers = Increase medication metabolism
(Carbamazepine, Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas)
--CYP450 inhibitors - -Inhibitors are medications that inhibit the metabolic activity of one or more of
the CYP450 enzymes. Medications that inhibit an enzyme potentially slows that enzyme's activity or
blocks the activity required for the metabolism of other medications, thereby increasing the levels of
medications dependent on that particular enzyme for biotransformation. Inhibitors = decrease
medication metabolism (Valproate, Isoniazid, Sulfonamides, Amiodarone, Chloramphenicol,
Ketoconazole, Grapefruit Juice, Quinidine)
--cultural influences in prescribing - -The greatest concern surrounding race-based therapy has to do
with genetic variability. We know there is great diversity within and among racial groups; therefore,
a "one fits all" approach based on race is unwise. Still, we can use known associations to guide
choices. For example, differences in metabolism between people with East Asian and European
heritage are common. The provider can use this knowledge to guide initial dosing (with adjustment,
as indicated based on response) if genetic testing is not feasible or warranted
--Polypharmacy: Definition, challenges, and outcomes - -treatment with multiple drugs
greatly increases the risk for interactions. Some of these interactions are negligible, but some can
have life-threatening consequences. It is of crucial importance to ask the patient about all current
drugs, including over-the-counter (OTC) medications and other herbal preparations. Many patients
do not consider OTC or alternative pharmaceuticals as "medications" and may not mention them
unless you ask specifically.
--Acute Pain Management - -
--Chronic Pain Management - -
--Opioid Management - -
--Regulations of Controlled Substances - -The U.S. Department of Justice Drug Enforcement Agency
(DEA) coordinates with local, state, and federal agents to reduce illicit drug use. The DEA enacted the
Controlled Substances Act (CSA) in 1970 to regulate drugs and other substances based on their
potential for abuse and dependency. Five schedules of controlled substances were created that are
updated annually. Classes of scheduled substances include narcotics, depressants, stimulants,
hallucinogens, and anabolic steroids. The DEA issues eligible providers with a registration number to
write prescriptions for controlled substances. Characteristics of a valid DEA number include:
-The first letter identifies the type of provider: A=before 1985; B=after 1985; F=after 2007; M=nurse
practitioner or physician assistant
-The 2nd letter the 1st letter of the provider's last name at the time of initial registration
, Example: Tammy Greene applies for and receives a DEA number of MG2705208
M=nurse practitioner and G=Greene
--Opioid Epidemic & Responsible Prescribing - -
--Opioid Use Disorder - -a pattern of use that leads to significant impairment or distress. Typically,
this disorder is marked by unsuccessful efforts to reduce or control use resulting in the inability to
fulfill work, school, or home responsibilities. Opioid use disorder is different from drug tolerance and
physical dependence, which may also exist. Opioid use creates high levels of positive reinforcement,
increasing the likelihood of continued use. It is often a chronic lifelong disorder, leading to serious
consequences such as disability and death. Although it is similar to other substance use disorders, it
has distinct features that have fueled the current opioid epidemic. Opioids can lead to physical
dependence in only 4-8 weeks. Abruptly stopping use in chronic users leads to severe symptoms,
which motivates continued use to prevent withdrawal. The 2016 CDC guidelines for prescribing
opioids recommends calculating the total daily dose of opioids to help identify patients who might
benefit from the reduction or tapering of opioids, given the risk of overdose
--State Prescription Drug - -Clinicians should review the patient's history of controlled substance
prescriptions using state prescription drug monitoring program (PDMP) data to determine whether
the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for
overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and
periodically during opioid therapy for chronic pain, ranging from every prescription to every 3
months.
--Monitoring Programs - -safeguards to address the opioid public health crisis include prescription
drug monitoring programs (PDMPs). These electronic databases enable providers to access
information regarding a patient's prescription history of controlled substances. Nearly all states have
implemented PDMPs, and some states require providers to check the PDMP before prescribing
controlled substances. According to the CDC (2020), PDMPs have shown promising results in
changing prescribing behaviors, decreasing the use of multiple providers by patients, and decreasing
substance abuse treatment admissions.
--Drug Schedules - -Each drug preparation regulated under the CSA has been assigned to one of five
categories: schedule I, II, III, IV, or V. Drugs in schedule I have a high potential for abuse and no
approved medical use in the United States. In contrast, drugs in schedules II through V all have
approved applications. Assignment to schedules II through V is based on abuse potential and
potential for causing physical or psychological dependence. Of the drugs that have medical
applications, those in schedule II have the highest potential for abuse and dependence. Drugs in the
remaining schedules have decreasing abuse and dependence liabilities.
--The therapeutic window - -is the amount of a medication between the amount that gives an effect
(effective dose) and the amount that gives more adverse effects than desired effects. For instance,
medication with a small pharmaceutical window must be administered with care and control, e.g. by
frequently measuring blood concentration of the drug, since it easily loses effects or gives adverse
effects
--Antagonist - -A drug that attenuates the effect of an agonist. Can be competitive or non-
competitive, each of which can be reversible or irreversible. A competitive antagonist binds to the
same site as the agonist but does not activate it, thus blocks the agonist's action. A non-competitive
antagonist binds to an allosteric (non-agonist) site on the receptor to prevent activation of the
actual exam 2025 test 100% solved 2025!!
APRN prescribing role - -Prescriptive authority for nurse practitioners also regulates prescribing
rights beyond medications and controlled substances. These rights include therapeutic devices and
services and are outlined in state practice laws and regulations and include Durable Medical
Equipment (DME) such as wheelchairs, power scooters, hospital beds, portable oxygen equipment,
handicap placards, etc. and medical services such as Physical Therapy (PT), Occupational Therapy
(OT), home health services, etc. Prescriptive authority encompasses more than writing a prescription
correctly. It requires adherence to ethical guidelines to ensure that patients are safeguarded from
harm. Ethical prescribing starts with being well-informed about medications. Mechanism of action,
efficacy, and safety are important considerations, as are a patient's distinct needs and
circumstances, including the number of medications prescribed (Mitchell & Oliphant, 2016). Most
patients receiving a prescription are taking other medications, whether prescription or over-the-
counter. Appropriate selection, dosing, and duration of pharmaceutical agents are key to maximizing
outcomes and minimizing adverse effects
--benefits of full practice authority - -Nurse practitioners have the autonomy to evaluate patients,
diagnose, order and interpret tests, initiate and manage treatments and prescribe medications,
including controlled substances without physician oversight
--promoting positive outcomes through prudent prescribing practices - -Administering medications
and prescribing medications are two distinct processes. Prescription writing requires prudent and
deliberate decision-making processes to maintain patient safety and reduce liability, including:
*documentation of a provider-patient relationship for the recipient of the prescribed medications
*documentation of a thorough history and physical examination for the recipient
*documentation of discussions regarding risk factors, side effects, or therapy options
*documentation of drug monitoring or titration plan, if applicable
*documentation of consultations, if any
avoidance of prescribing medications for self, family, or friends
Rational drug selection requires a logical approach that includes the formulation of a diagnosis based
on clinical reasoning and the selection and monitoring of the most appropriate pharmacological
treatment
Considerations include: Cost, guidelines, availability, interactions, side effects, allergies,
hepatic/renal functions, need for monitoring, & special populations
--Beer's Criteria - -identifies drugs with a high likelihood of causing adverse effects in older adults.
Accordingly, drugs on this list should generally be avoided in adults older than 65 years except when
the benefits are significantly greater than the risks.
--Pharmacodynamics - -the study of the biochemical and physiologic effects of drugs on the body
and the molecular mechanisms by which those effects are produced
--Pharmacokinetics - -the study of drug movement throughout the body
,--Pharmacogenomics - -the study of how genes affect a person's response to drugs. The purpose of
this is to combine the sciences of genomics and pharmacology to provide individualized, targeted,
safe drug therapies to patients
--CYP450 inducers - -Inducers are xenobiotics (medications and environmental agents) that elevate
CYP450 enzyme activity by increasing enzyme synthesis. This action leads to additional sites available
for biotransformation. The increased number of sites enhances medication metabolism, decreasing
the concentration of the "parent drug" while increasing metabolite production.
Inducers = Increase medication metabolism
(Carbamazepine, Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas)
--CYP450 inhibitors - -Inhibitors are medications that inhibit the metabolic activity of one or more of
the CYP450 enzymes. Medications that inhibit an enzyme potentially slows that enzyme's activity or
blocks the activity required for the metabolism of other medications, thereby increasing the levels of
medications dependent on that particular enzyme for biotransformation. Inhibitors = decrease
medication metabolism (Valproate, Isoniazid, Sulfonamides, Amiodarone, Chloramphenicol,
Ketoconazole, Grapefruit Juice, Quinidine)
--cultural influences in prescribing - -The greatest concern surrounding race-based therapy has to do
with genetic variability. We know there is great diversity within and among racial groups; therefore,
a "one fits all" approach based on race is unwise. Still, we can use known associations to guide
choices. For example, differences in metabolism between people with East Asian and European
heritage are common. The provider can use this knowledge to guide initial dosing (with adjustment,
as indicated based on response) if genetic testing is not feasible or warranted
--Polypharmacy: Definition, challenges, and outcomes - -treatment with multiple drugs
greatly increases the risk for interactions. Some of these interactions are negligible, but some can
have life-threatening consequences. It is of crucial importance to ask the patient about all current
drugs, including over-the-counter (OTC) medications and other herbal preparations. Many patients
do not consider OTC or alternative pharmaceuticals as "medications" and may not mention them
unless you ask specifically.
--Acute Pain Management - -
--Chronic Pain Management - -
--Opioid Management - -
--Regulations of Controlled Substances - -The U.S. Department of Justice Drug Enforcement Agency
(DEA) coordinates with local, state, and federal agents to reduce illicit drug use. The DEA enacted the
Controlled Substances Act (CSA) in 1970 to regulate drugs and other substances based on their
potential for abuse and dependency. Five schedules of controlled substances were created that are
updated annually. Classes of scheduled substances include narcotics, depressants, stimulants,
hallucinogens, and anabolic steroids. The DEA issues eligible providers with a registration number to
write prescriptions for controlled substances. Characteristics of a valid DEA number include:
-The first letter identifies the type of provider: A=before 1985; B=after 1985; F=after 2007; M=nurse
practitioner or physician assistant
-The 2nd letter the 1st letter of the provider's last name at the time of initial registration
, Example: Tammy Greene applies for and receives a DEA number of MG2705208
M=nurse practitioner and G=Greene
--Opioid Epidemic & Responsible Prescribing - -
--Opioid Use Disorder - -a pattern of use that leads to significant impairment or distress. Typically,
this disorder is marked by unsuccessful efforts to reduce or control use resulting in the inability to
fulfill work, school, or home responsibilities. Opioid use disorder is different from drug tolerance and
physical dependence, which may also exist. Opioid use creates high levels of positive reinforcement,
increasing the likelihood of continued use. It is often a chronic lifelong disorder, leading to serious
consequences such as disability and death. Although it is similar to other substance use disorders, it
has distinct features that have fueled the current opioid epidemic. Opioids can lead to physical
dependence in only 4-8 weeks. Abruptly stopping use in chronic users leads to severe symptoms,
which motivates continued use to prevent withdrawal. The 2016 CDC guidelines for prescribing
opioids recommends calculating the total daily dose of opioids to help identify patients who might
benefit from the reduction or tapering of opioids, given the risk of overdose
--State Prescription Drug - -Clinicians should review the patient's history of controlled substance
prescriptions using state prescription drug monitoring program (PDMP) data to determine whether
the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for
overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and
periodically during opioid therapy for chronic pain, ranging from every prescription to every 3
months.
--Monitoring Programs - -safeguards to address the opioid public health crisis include prescription
drug monitoring programs (PDMPs). These electronic databases enable providers to access
information regarding a patient's prescription history of controlled substances. Nearly all states have
implemented PDMPs, and some states require providers to check the PDMP before prescribing
controlled substances. According to the CDC (2020), PDMPs have shown promising results in
changing prescribing behaviors, decreasing the use of multiple providers by patients, and decreasing
substance abuse treatment admissions.
--Drug Schedules - -Each drug preparation regulated under the CSA has been assigned to one of five
categories: schedule I, II, III, IV, or V. Drugs in schedule I have a high potential for abuse and no
approved medical use in the United States. In contrast, drugs in schedules II through V all have
approved applications. Assignment to schedules II through V is based on abuse potential and
potential for causing physical or psychological dependence. Of the drugs that have medical
applications, those in schedule II have the highest potential for abuse and dependence. Drugs in the
remaining schedules have decreasing abuse and dependence liabilities.
--The therapeutic window - -is the amount of a medication between the amount that gives an effect
(effective dose) and the amount that gives more adverse effects than desired effects. For instance,
medication with a small pharmaceutical window must be administered with care and control, e.g. by
frequently measuring blood concentration of the drug, since it easily loses effects or gives adverse
effects
--Antagonist - -A drug that attenuates the effect of an agonist. Can be competitive or non-
competitive, each of which can be reversible or irreversible. A competitive antagonist binds to the
same site as the agonist but does not activate it, thus blocks the agonist's action. A non-competitive
antagonist binds to an allosteric (non-agonist) site on the receptor to prevent activation of the
